Telmisartan prevented cognitive decline partly due to PPAR-gamma activation

Biochemical and Biophysical Research Communications
Masaki MogiMasatsugu Horiuchi

Abstract

Telmisartan is a unique angiotensin receptor blocker (ARB) and partial agonist of peroxisome proliferator-activated receptor (PPAR)-gamma. Here, we investigated the preventive effect of telmisartan on cognitive decline in Alzheimer disease. In ddY mice, intracerebroventricular injection of Abeta 1-40 significantly attenuated their cognitive function evaluated by shuttle avoidance test. Pretreatment with a non-hypotensive dose of telmisartan significantly inhibited such cognitive decline. Interestingly, co-treatment with GW9662, a PPAR-gamma antagonist, partially inhibited this improvement of cognitive decline. Another ARB, losartan, which has less PPAR-gamma agonistic effect, also inhibited Abeta-injection-induced cognitive decline; however the effect was smaller than that of telmisartan and was not affected by GW9662. Immunohistochemical staining for Abeta showed the reduced Abeta deposition in telmisartan-treated mice. However, this reduction was not observed in mice co-administered GW9662. These findings suggest that ARB has a preventive effect on cognitive impairment in Alzheimer disease, and telmisartan, with PPAR-gamma activation, could exert a stronger effect.

References

Feb 15, 2001·Archives of Internal Medicine·W H BirkenhägerJ A Staessen
Jul 22, 2005·Lancet Neurology·Chengxuan QiuLaura Fratiglioni
Nov 16, 2005·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·G Stennis WatsonSuzanne Craft
Mar 7, 2006·Experimental Neurology·Ward A PedersenGleb R Haynatzki
Jun 21, 2006·The American Journal of Cardiology·Carlos M Ferrario, William B Strawn

❮ Previous
Next ❯

Citations

Apr 13, 2011·Psychopharmacology·Rasha MechaeilJennifer Rusted
Aug 15, 2012·Psychopharmacology·Jan Józef BraszkoPiotr Jakubów
Sep 8, 2010·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Feng-Shiun ShieIng-Kang Ho
Mar 28, 2013·Drugs & Aging·Hitomi KurinamiRyuichi Morishita
Sep 4, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masaki Mogi, Masatsugu Horiuchi
Mar 6, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Jun IwanamiMasatsugu Horiuchi
Nov 6, 2012·Nature Reviews. Drug Discovery·Anne CorbettClive Ballard
Jan 16, 2013·International Journal of Hypertension·Marie-Odile Guimond, Nicole Gallo-Payet
Jun 28, 2015·Brain : a Journal of Neurology·Sonia VillapolAviva J Symes
Mar 20, 2016·Cellular and Molecular Neurobiology·Edith HamelXin-Kang Tong
Nov 2, 2014·American Journal of Hypertension·Sonia Villapol, Juan M Saavedra
May 7, 2015·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Jaspreet KalraAbu Bakar Abdul Majeed
Jul 9, 2016·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Panayiota PapadopoulosEdith Hamel
Jan 20, 2017·Advanced Pharmaceutical Bulletin·Asma RavanbakhshMohammad Reza Rashidi
Apr 2, 2014·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Yusuke FukuiKoji Abe
Nov 11, 2014·Journal of Cardiovascular Pharmacology·Edith Hamel
Oct 6, 2011·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Fei JingMasatsugu Horiuchi
Dec 12, 2017·Journal of Alzheimer's Disease : JAD·Patrick G KehoeYoav Ben-Shlomo
May 18, 2016·PloS One·Nofar TorikaSigal Fleisher-Berkovich
Dec 25, 2009·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Rüdiger Hardeland
Sep 21, 2011·Geriatrics & Gerontology International·Kazumasa KumeToshihiko Iwamoto
Jan 11, 2014·Journal of Hypertension·Wei-Che ChiuUNKNOWN Health Data Analysis in Taiwan (hDATa) Research Group
Jan 13, 2016·Journal of Alzheimer's Disease : JAD·Daniel A NationUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Dec 24, 2019·Expert Review of Neurotherapeutics·Thibaud LebouvierRégis Bordet
Sep 1, 2012·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Anjana BaliAmteshwar Singh Jaggi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.